-
Shanghai’s EnjoSim Secures Tens of Millions in Pre-Series A Funding for Expansion
•
EnjoSim, a Shanghai-based developer of microbiologic self-administration systems, has reportedly secured tens of millions of renminbi in a Pre-Series A financing round. The funds will be directed towards scaling up the operation of multiple fully automatic production lines, developing new products, and expanding the company’s business reach both within China…
-
Pfizer Eyes Further ADC Expansion, Potentially in China, Says Chief Oncology Officer
•
Dr. Chris Boshoff, Pfizer (NYSE: PFE)’s recently appointed chief oncology officer, disclosed in an interview with FiercePharma.com on the margins of the JP Morgan Healthcare Conference that the company is contemplating additional strategic deals, particularly in the realm of antibody drug conjugates (ADCs), with a focus that may include Chinese…
-
CARsgen Therapeutics Gets NMPA Approval for CAR-T Therapy CT011 in Hepatocellular Carcinoma
•
China-based CARsgen Therapeutics Holdings Ltd (HKG: 2171) has announced that it has received approval from the National Medical Products Administration (NMPA) to conduct a clinical study for its chimeric antigen receptor (CAR)-T therapy, CT011. The study will focus on patients with GPC3 positive stage IIIa hepatocellular carcinoma (HCC) who are…
-
Simcere Pharmaceutical Group Gets NMPA Green Light for USP1 Inhibitor SIM0501
•
Simcere Pharmaceutical Group (HKG: 2096) has announced that it has received clinical trial approval from the National Medical Products Administration (NMPA) for its cancer drug candidate SIM0501, intended for the treatment of advanced solid tumors. SIM0501 is a small-molecule inhibitor of ubiquitin specific peptidase 1 (USP1), a protein that is…
-
Ant Insurance Reports 23% Surge in Health Insurance Payouts, Processing 4.69 Million Claims in 2023
•
Ant Insurance, a platform integrated within Alibaba’s Alipay app, reported a 23% year-on-year increase in health insurance payouts from partner insurers over the past 12 months. The surge in claims was facilitated by Ant’s EasyClaims (AnXinPei) feature, which streamlined online claims processing, resulting in a total of 4.69 million healthcare…
-
Myrobalan Therapeutics Secures $24 Million in Series A Funding with Strong Chinese Investor Support
•
Myrobalan Therapeutics, a Massachusetts-based biotech firm, has successfully completed a $24 million Series A funding round, featuring significant participation from Chinese investors. The financing was led by Shenzhen-based Co-win Ventures, with contributions from both new and existing investors, including Guan Zi Equity Investment (Li Shui) Partnership, 3E Bioventures Capital, and…
-
Huadong Medicine’s Relmapirazin Approval Filing Accepted by NMPA for GFR Measurement
•
Huadong Medicine Co., Ltd (SHE: 000963), based in China, has announced that its market approval filing for relmapirazin, a Category 1 chemical drug and fluorescent tracer for measuring glomerular filtration rate (GFR), has been accepted for review by the National Medical Products Administration (NMPA). This tracer is designed for use…
-
Lepu Medical Secures NMPA Approval for Innovative Coronary Intravascular Impact Waveguide Tube
•
Lepu Medical Technology (Beijing) Co., Ltd (SHE: 300003), a China-based provider of cardiovascular disease solutions, has received marketing approval from the National Medical Products Administration (NMPA) for its proprietary disposable coronary intravascular impact waveguide tube. This Category III device is now authorized for use in the pre-treatment and balloon dilation…
